Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...

For older adults with type 2 diabetes, use of GLP-1 RAs is associated with a modestly lower risk for depression compared with DPP-4i use.

While one study found lower rates of preterm birth alongside higher rates of hypertensive disorders, another found fewer ...

A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.

RAs are transforming obesity treatment, demonstrating substantial weight loss and metabolic improvements with lifestyle ...

The WEGOVY market has experienced significant growth, driven by rising obesity rates and increasing demand for effective weight-loss treatments. Novo Nordisk's blockbuster drug has seen strong ...

Use of GLP-1 receptor agonists to treat type 2 diabetes is not associated with an increased risk of suicidality compared with ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic ...

It’s normal to have lots of questions when you start a new prescription medication. Whether you can drink alcohol might be at ...

New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...

On his Instagram profile, the “Queer Eye” star Jonathan Van Ness detailed that he lost 30 kg with GLP-1 weight-loss ...

Imagine a future where the grip of cocaine use disorder can be loosened, where cravings fade, and the risk of relapse diminishes.